Tuesday, September 18, 2018
Could this be Warren Buffett’s Valentine’s Day Massacre? On February 14, Berkshire Hathaway filed a 13-F form with the SEC, updating the market on its quarterly holdings. It showed a surprising fourth-quarter acquisition – Israel’s Teva Pharmaceutical Industries, Ltd. (NYSE: TEVA). Berkshire bought 18.9 million shares for $358 million. Following the stock’s inevitable “Buffett Bounce,” […]
Remember the days when political strife and geopolitical volatility used to spook investors and send tremors through the stock market? I do… but those memories are fading fast. Given the current climate, you’d think the phrase “market jitters” would appear more often. After all, if there’s one thing the market hates, it’s uncertainty. Yet stocks […]
Imagine a world where a person’s cells are “re-engineered” to recognize and attack cancer, so that conventional therapies are not needed. Science fiction, right? Thankfully, no! It’s all part of the move toward personalized medicine. Welcome to the world of chimeric antigen receptor cell therapy or Car-T, which has given hope to thousands of blood […]
Climbing almost 10% in one week alone, it looks like the biotech sector is back in business. If you’re looking to gain some exposure to the rally but don’t want to invest in small, risky pot-shots, take a look at these two stocks. They’re the only two that Growth Stock Advisor Tony Daltorio would buy […]
As a stockbroker, I would tell clients and prospects that insiders sell their company stocks for all sorts of reasons. They wanted to buy a car or a house or a football team (a play on a Pink Floyd lyric from the song Money). While they sell for anything, I would proclaim they only buy […]
Stocks with major insiders buying up shares are some of the most attractive investments in the market right now. With mounting uncertainty about what growth the economy can achieve in 2016, trusting in the people that know their businesses best is a safe bet. Investors are always interested in low priced stocks. That’s why you […]
De-risk your portfolio with these four undervalued dividend payers that you can watch grow inside of your portfolio. With the market pulling back again, now is a great time to start adding shares while they’re cheap. After a strong run in March, the stock market appears to be taking a step back. We saw the […]
Follow any of these three easy to understand, step-by-step strategies that detail exactly how any investor can profit from the collapse in biotech. The biotech sector is a bursting bubble. Unfortunately, making money from a bursting bubble requires investors to go short on a stock. Shorting a stock exposes an investor to a theoretically infinite […]
Big biotech is about to go on a shopping spree to replenish their pipelines as many small cap biotechs are selling for lows not seen since 2011. Here are three likely candidates that might get snatched up soon for big premiums. Few sectors of the stock market have been hit harder in 2016 than the […]
M&A activity is about to really heat up in the small cap sector and these three picks look like imminent targets. Large multi-national companies are starved for growth and, with their war-chests of cash, will spend heavily on fast-growth small cap stocks. M&A activity is about to really heat up in the small cap sector […]
